| Original language | English |
|---|---|
| Pages (from-to) | 657-659 |
| Number of pages | 3 |
| Journal | Modern Rheumatology |
| Volume | 25 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2015 |
ASJC Scopus subject areas
- Rheumatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Issues associated with the ministry of health, labour and welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides : Reclassification of patients in the prospective cohort study of remission induction therapy in japanese patients with ANCA-associated vasculitides according to the MHLW criteria. / Sada, Kenei; Yamamura, Masahiro; Harigai, Masayoshi et al.
In: Modern Rheumatology, Vol. 25, No. 4, 2015, p. 657-659.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Issues associated with the ministry of health, labour and welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides
T2 - Reclassification of patients in the prospective cohort study of remission induction therapy in japanese patients with ANCA-associated vasculitides according to the MHLW criteria
AU - Sada, Kenei
AU - Yamamura, Masahiro
AU - Harigai, Masayoshi
AU - Fujii, Takao
AU - Arimura, Yoshihiro
AU - Makino, Hirofumi
N1 - Funding Information: This work was supported by grants from the Ministry of Health, Labour and Welfare, Japan (nannti-ippann-004). The authors thank Keiko Hongo, Kumiko Muraki, Eri Katsuyama, Takayuki Katsuyama, Haruki Watanabe, Mariko Narazaki, Noriko Tatebe, Yoshinori Matsumoto, Ryutaro Yamanaka, and Kouichi Sugiyama for their great assistance in data management. Funding Information: MH has research grants and/or honoraria from Abbvie Japan Co., Ltd., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma, Ltd., and Pfizer Japan Inc. TF has received research grants from Abbvie Japan Co., Ltd., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co, Takeda Pharmaceutical Co., Ltd., and Pfizer Japan Inc. HM is a consultant for AbbVie, Astellas and Teijin, receives speaker honoraria from Astellas, Boehringer-ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Takeda, and Tanabe Mitsubishi, and receives grant support from Astellas, Boehringer-ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, Mochida,MSD, Novartis, Novo Nordisk, Pfizer, Takeda, and Tanabe Mitsubishi.
PY - 2015
Y1 - 2015
UR - http://www.scopus.com/inward/record.url?scp=84934908592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934908592&partnerID=8YFLogxK
U2 - 10.3109/14397595.2014.982270
DO - 10.3109/14397595.2014.982270
M3 - Article
C2 - 25496407
AN - SCOPUS:84934908592
SN - 1439-7595
VL - 25
SP - 657
EP - 659
JO - Japanese Journal of Rheumatology
JF - Japanese Journal of Rheumatology
IS - 4
ER -